Chemical Works of Gedeon Richter Plc Logo

Chemical Works of Gedeon Richter Plc

Develops and manufactures drugs for women's health, CNS, and cardiovascular diseases.

RICHT | BUD

Overview

Corporate Details

ISIN(s):
HU0000067624 (+3 more)
LEI:
549300J6ZJW5IH4WEE46
Country:
Hungary
Address:
GYOMROI UT 19-21, 1103 BUDAPEST
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemical Works of Gedeon Richter Plc. is a multinational, vertically integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of medicinal products. The company's core therapeutic areas include women's health, central nervous system disorders, and cardiovascular diseases, with additional activity in oncology. Its portfolio consists of original research drugs, active pharmaceutical ingredients (APIs), and generic medicines. Founded in 1901, Gedeon Richter focuses on delivering high-value therapies to improve the quality of life for patients globally.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-26 09:12
Transaction in Own Shares
Transactions with Treasury Shares
Hungarian 192.9 KB
2025-11-26 09:12
Transaction in Own Shares
Transactions with Treasury Shares
English 295.6 KB
2025-11-25 09:03
Transaction in Own Shares
Transactions with Treasury Shares
Hungarian 229.2 KB
2025-11-25 09:03
Transaction in Own Shares
Transactions with Treasury Shares
English 199.8 KB
2025-11-06 12:59
Related Party Transaction
Subsidiaries transactions Q1-Q3 2025
English 179.1 KB
2025-11-06 12:59
Related Party Transaction
Subsidiaries transactions Q1-Q3 2025
Hungarian 238.5 KB
2025-11-06 06:03
Investor Presentation
edeon Richter Plc. - Company presentation Q3 2025
Hungarian 1.4 MB
2025-11-06 06:03
Investor Presentation
edeon Richter Plc. - Company presentation Q3 2025
English 1.4 MB
2025-10-31 14:11
Regulatory News Service
Voting rights, registered capital
Hungarian 244.7 KB
2025-10-31 14:11
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
English 207.0 KB
2025-10-09 10:32
Regulatory News Service
Half-year report for the period ended 30 June 2025 published on August 6, 2025…
Hungarian 1.4 MB
2025-10-09 10:32
Interim Report
Half-year report for the period ended 30 June 2025 published on August 6, 2025…
English 1.4 MB
2025-09-30 14:34
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
Hungarian 243.0 KB
2025-09-30 14:34
Declaration of Voting Results & Voting Rights Announcements
Voting rights, registered capital
English 206.1 KB
2025-09-29 08:00
Regulatory News Service
Richter and Hikma receive FDA approval for denosumab biosimilars EnobyTM and Xt…
Hungarian 420.4 KB

Automate Your Workflow. Get a real-time feed of all Chemical Works of Gedeon Richter Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemical Works of Gedeon Richter Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chemical Works of Gedeon Richter Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.